HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Blair, P. B. Articles by Yagi, M. J. Search for Related Content PubMed Articles by Blair, P. B. Articles by Yagi, M. J.

In Vitro Detection of Immune Responses to MTV-Induced Mammary Tumors: Activity of Spleen Cell Preparations from Both MTV-Free and MTV-Infected Mice¹

From the Department of Bacteriology and Immunology and the Cancer Research Laboratory, University of California, Berkeley, California 94720

Abstract

BALB/cfC3H mice, neonatally infected with mammary tumor virus (MTV), can respond immunologically to MTV-associated antigens on tumor cells: spleen cells from both normal adult females and females which have developed MTV-induced mammary tumors significantly inhibit growth and survival of target tumor cells in culture. Essentially the same level of reactivity is observed in normal BALB/cfC3H females between the ages of 8 and 32 weeks. Tumor-donor spleen cells are considerably more active. An unexpected finding was the observation that supposedly MTV-free BALB/c adult females also possess spleen cells specifically reactive against MTV-induced mammary tumor cells. The only mice tested whose spleen cells were not reactive were BALB/c females younger than 14 weeks of age. BALB/c serum blocked activity of BALB/c but not BALB/cfC3H spleen cells, and BALB/cfC3H serum blocked activity of BALB/cfC3H but not BALB/c spleen cells; thus, the two groups of mice are responding to different MTV-associated antigens on the target cells. Tumor-donors respond to both types of antigens, and also to tumor-specific antigens.

Footnotes

¹ This work was supported by Public Health Service research Grant CA-05388 from the National Cancer Institute, and by cancer research funds of the University of California.